Biotech Ignites: Rani’s $1B Chugai Deal Sparks Sector Rally, Kezar Pivots, and AI-Driven Drugmakers Eye New Highs

October 17, 2025

DENVER, Colo., Oct 17, 2025 (247marketnews.com)- The biotech sector lit up this morning as Rani Therapeutics Holdings (NASDAQ:RANI) surged on news of a game-changing partnership with Chugai Pharmaceutical, part of the Roche (OTCQX:RHHBY) The collaboration, centered on Rani’s RaniPill oral biologics platform, could be worth over $1 billion if all milestones are met. An initial $10 million upfront payment anchors the deal, with options for five additional drug targets. Simultaneously, Rani announced a $60.3 million private placement led by top-tier biotech investors, giving it a cash runway into 2028. The stock popped over 50% premarket, reaffirming investor belief in the future of needle-free drug delivery.
Meanwhile, Artiva Biotherapeutics (NASDAQ:ARTV) is climbing on the announcement that it has secured FDA Fast Track designation for its lead candidate AlloNK in refractory rheumatoid arthritis. With over 100,000 U.S. patients lacking effective treatment and early trial data pointing to deep B-cell depletion, Artiva is aiming for a pivotal trial in 1H 2026. The company is also preparing to release new safety and translational data in mid-November, potentially solidifying its position as a scalable outpatient-ready therapy option—something CAR-T and other cell therapies often lack.
In contrast, Kezar Life Sciences (NASDAQ:KZR) is taking a step back, announcing a strategic review process after the FDA cancelled a key Type C meeting on its AIH drug, zetomipzomib. Despite showing encouraging data in a Phase 2 trial, regulatory roadblocks have forced Kezar to halt progression and explore M&A or other strategic alternatives. With $90.2 million in cash and a shareholder rights plan extension in place, KZR appears focused on protecting shareholder value during this uncertain pivot.
Elsewhere in the sector, Kraig Biocraft Laboratories (OTCQB:KBLB) is quietly making waves in the circular fashion movement with its genetically enhanced BAM 1 Alpha spider silk silkworms. As global fashion shifts toward sustainability, KBLB’s biodegradable silk could carve out a niche in a $200B+ circular fashion market by 2030. Even a 1% share of the luxury market could represent billions in upside, making the company’s IP-protected platform one to watch.
XORTX Therapeutics (NASDAQ:XRTX), Femasys (NASDAQ:FEMY), and Achieve Life Sciences (NASDAQ:ACHV) are also catching early speculative attention, riding on renewed enthusiasm in biotech microcaps following high-profile deals. Meanwhile, ATAI Life Sciences (NASDAQ:ATAI) bulls argue the psychedelic platform could benefit from rising global mental health investments and pending Phase 2 readouts.
For more information about Kraig Labs’ spider silk technology and partnership opportunities, visit www.kraiglabs.com
Please click here to read the full Kraig Labs analyst report on 247marketnews.com.
Contact sales@247marketnews.com for Analyst Report coverage and other investor/public relations services.
PAID EDITORIAL DISCLOSURE: This is a paid editorial communication intended for informational purposes only. 247 is a third-party media provider and has been compensated by one or more featured companies for providing ongoing KBLB market outreach and other services.. This press release may include technical analysis and should not be construed as financial or investment advice. Trading stocks involves risks, and readers should consult with their financial advisor before making investment decisions. Please review 247’s Full Disclaimer https://www.247marketnews.com/disclaimer/. Please go to https://247marketnews.com/kblb-disclosure/ for further KBLB and 247marketnews.com disclosure information.

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

CONTACT:
24/7 Market News
Editor@247marketnews.com

Related news for (KBLB, ARTV, RANI, KZR, XRTX, RHHBY)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.